系统性红斑狼疮(Systemic lupus erythematosus, SLE)是一种慢性、全身多系统受累的自身免疫性疾病。其病因和发病机制尚未完全明确,有研究表明B细胞过度增殖、活化是SLE发病至关重要的环节,也是造成全身多脏器损害的病理基础。因此B细胞成为SLE治疗的新型靶点,本综述主要围绕B细胞相关靶向治疗进展进行讨论,包括靶向B细胞表面抗原、靶向B细胞因子、共刺激阻断、酪氨酸蛋白激酶抑制剂等方面,重点介绍其已经结束或正在进行的临床试验以及实际上市后的临床应用。

Systemic lupus erythematosus (SLE) is a chronic, Systemic, multi-system autoimmune disease. The etiology and pathogenesis of SLE have not been completely clarified. Some studies have shown that excessive proliferation and activation of B cells is a crucial link in the pathogenesis of SLE, and also the pathological basis of systemic multi-organ damage. Therefore, B cells have become a new target for the treatment of SLE. This review focuses on the progress of B cell-related targeted therapies. Including target cell surface antigen B resistance, targeted B cell factor, stimulating block, protein tyrosine kinase inhibitors, etc., focus on the end or ongoing clinical trials and post-marketing clinical application.

内蒙古自然基金项目